Podcast: How MyFiziq is helping with health management during the COVID-19 pandemic
COVID-19 has presented the biggest health and economic challenges the world has faced since the Great Depression.
Yet, there is still an inability to determine why some people contract the disease, while others present little or no symptoms at all.
What we can do, however, is better identify those who may be at more risk than others, including those with underlying health conditions such as heart disease, lung disease, diabetes and overweight/obesity.
MyFiziq is well in the fight to encourage healthy living and battle the effects of obesity and has developed a patented mobile application that allows users to track body shapes and dimensions while performing everyday activities.
The application measures body fat indirectly through machine learning and body shape analysis.
Speaking with Finfeed today is former bodybuilder and investment banker Vlado Bosanac, the man behind MyFiziq and the MyFiziq app, a digital measuring tool for the human form.
In the podcast below, we take a look at Vlado’s career, what drives him to succeed and how MyFiziq could change the weight management landscape.
MyFiziq is focused on delivering its app to several key verticals worth collectively trillions of dollars including health and fitness, medical and insurance, corporate wellness, apparel, telehealth and mobile health.
To learn more about the app and how it works, watch the video below.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.